BioLife Solutions

Forecast & Rating9 analysts currently cover BioLife Solutions, with about 11.1% giving a positive rating — meaning they expect the stock to rise. The average price target is $31.29, about 17.8% downside from the current price of $38.07. Price targets are fairly clustered, pointing to relatively aligned views. Historically, about 46.1% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on BioLife Solutions's outlook. Data as of Aug 10, 2026; for reference only and not investment advice.